Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.

Andrew B LassmanJuan Manuel Sepúlveda-SánchezTimothy F CloughesyJuan Miguel Gil-GilVinay K PuduvalliJeffrey J RaizerFilip Yves Francine De VosPatrick Y WenNicholas A Butowski Paul M J ClementMorris D GrovesCristóbal Belda-IniestaPierre GiglioHarris S SoiferSteven RowseyCindy XuFrancesca AvogadriGe WeiSusan MoranPatrick Roth

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

FGFR inhibitor monotherapy with infigratinib had limited efficacy in a population of patients with recurrent gliomas and different FGFR genetic alterations, but durable disease control lasting more than 1 year was observed in patients with tumors harboring FGFR1 or FGFR3 point mutations or FGFR3-TACC3 fusions. A follow-up study with refined biomarker inclusion criteria and centralized FGFR testing is warranted.

Keyphrases

phase ii study
high grade
open label
randomized controlled trial
squamous cell carcinoma
gene expression
clinical trial
dna methylation
locally advanced
copy number
study protocol